GlassScriptPhysician profile
Michael Patrick Hultin
NPI 1952866451
$4,245.13
in general payments reported to CMS, 2019-2025
33 companies · $546 in 2025
The $546 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,690 · 2022: $440 · 2023: $200 · 2024: $370 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.55 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $482.32 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Abbvie INC. | $456.98 | 2021 | |
| Amgen INC. | $379.56 | 2021-2025 | Tezspire |
| Corcept Therapeutics | $352.10 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $317.61 | 2024-2025 | Dupixent |
| Glaxosmithkline, LLC. | $275.69 | 2021-2025 | Nucala |
| Novo Nordisk INC | $173.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $171.65 | 2021 | |
| Lilly USA, LLC | $163.37 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $156.12 | 2021 | |
| Merck Sharp & Dohme LLC | $129.37 | 2021 | |
| Astellas Pharma US INC | $116.60 | 2021 | |
| Aerin Medical INC. | $109.85 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.73 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $93.61 | 2023-2025 | Inspire |
| Amarin Pharma, INC. | $80.55 | 2021 | |
| Eisai INC. | $70.89 | 2021 | |
| Smith+Nephew, INC. | $68.03 | 2022-2025 | |
| Lundbeck LLC | $63.07 | 2021 | |
| Arbor Pharmaceuticals, INC. | $62.15 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $54.32 | 2021 | |
| Genzyme Corporation | $47.76 | 2025 | |
| Esperion Therapeutics, INC. | $42.84 | 2021 | |
| Optos, INC. | $42.11 | 2021-2022 | |
| Acclarent, INC | $29.40 | 2022 | |
| Roche Diagnostics Corporation | $22.67 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $18.80 | 2025 | |
| Medtronic, INC. | $17.89 | 2023 | Propel |
| Phathom Pharmaceuticals, INC. | $16.50 | 2024 | Voquezna |
| Pfizer INC. | $14.93 | 2023 | |
| Mylan Specialty L.P. | $13.71 | 2021 | |
| Genentech USA, INC. | $5.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hultin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.